Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635 1637 1682
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17270832 | CATIONIC COMPOUNDS FOR DELIVERY OF NUCLEIC ACIDS | Final Rejection | The Regents of the University of California |
| 17743422 | TUNABLE ANCHOR FOR LIPOSOMAL SPHERICAL NUCLEIC ACID ASSEMBLY | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 17059736 | RNA INTERFERENCE-INDUCING NUCLEIC ACID INHIBITING NONCANONICAL TARGETS OF MICRO RNA, AND USE FOR SAME | Non-Final OA | Korea University Research and Business Foundation |
| 18142852 | OLIGONUCLEOTIDES FOR PMS1 MODULATION | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17601522 | AIM2 INHIBITORS AND USES THEREOF | Non-Final OA | University of Massachusetts |
| 18324191 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17974598 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17672771 | NEUROFILAMENT LIGHT CHAIN (NFL) AS A BIOMARKER FOR TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17044195 | Compositions Comprising Immune System Activators and Method of Using Same | Non-Final OA | The Trustees of Princeton University |
| 18056961 | MICRORNA-DEPENDENT MRNA SWITCHES FOR TISSUE-SPECIFIC MRNA-BASED THERAPIES | Final Rejection | Cornell University |
| 17769255 | GENE THERAPY FOR ALZHEIMER'S DISEASE | Non-Final OA | Cornell University |
| 17371357 | CMI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER, ATHEROSCLEROSIS, DIABETES AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES | Final Rejection | DEUTSCHES KREBS-FORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS |
| 17365307 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 17783591 | ANTISENSE GUIDE RNA WITH ADDED FUNCTIONAL REGION FOR EDITING TARGET RNA | Non-Final OA | Astellas Pharma Inc. |
| 17420934 | CRISPR COMPOSITIONS AND METHODS FOR PROMOTING GENE EDITING OF ADENOSINE DEAMINASE 2 (ADA2) | Final Rejection | EmendoBio Inc. |
| 17635322 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | Non-Final OA | LONZA SALES AG |
| 17284919 | The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy | Final Rejection | The Brigham and Women`s Hospital, Inc. |
| 18256428 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | Non-Final OA | John WANG |
| 17605998 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | WAVE LIFE SCIENCES LTD. |
| 17426511 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Non-Final OA | WAVE LIFE SCIENCES LTD. |
| 18040961 | ARTIFICIAL EXPRESSION CONSTRUCTS FOR MODULATING GENE EXPRESSION IN STRIATAL NEURONS | Non-Final OA | Allen Institute |
| 18019449 | NUCLEIC ACID CONSTRUCTS AND USES THEREOF FOR TREATING SPINAL MUSCULAR ATROPHY | Non-Final OA | HANGZHOU EXEGENESIS BIO LTD. |
| 18005514 | COMPOSITIONS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | Non-Final OA | COLD SPRING HARBOR LABORATORY |
| 17934428 | THERAPEUTICS FOR HAPLOINSUFFICIENCY CONDITIONS | Non-Final OA | QUELLTX, INC. |
| 17794673 | METHODS AND COMPOSITIONS FOR GENERATING TYPE 1 VESTIBULAR HAIR CELLS | Non-Final OA | Decibel Therapeutics, Inc. |
| 17636450 | COILED-COIL MEDIATED TETHERING OF CRISPR/CAS AND EXONUCLEASES FOR ENHANCED GENOME EDITING | Non-Final OA | Kemijski Institut |
| 17425058 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF OCULAR DISEASES AND CONDITIONS | Final Rejection | Tufts Medical Center, Inc. |
| 17616107 | HUMAN HEAD AND NECK CANCER TREATMENT | Final Rejection | CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy